Ex-Celgene chief Mark Alles, former Goldfinch Bio leader Tony Johnson are back in the game as CEOs

→ For the first time since he sold Cel­gene to Bris­tol My­ers Squibb for $74 bil­lion in 2019, Mark Alles is a CEO again. Alles had been chair­ing the board at TORL Bio­ther­a­peu­tics, an an­ti­body mak­er from UCLA’s Den­nis Sla­m­on, and will now pace the side­lines as CEO of the com­pa­ny. Since the Cel­gene buy­out, Alles has shown up oc­ca­sion­al­ly in Peer Re­view by tak­ing board ap­point­ments, in­clud­ing the role of chair­man at AI Pro­teins, Wu­gen and Turn­ing Point Ther­a­peu­tics, which al­so caught the eye of Bris­tol My­ers. Look­ing to cash in on the an­ti­body-drug con­ju­gate craze, TORL launched last April and nabbed $158 mil­lion in Se­ries B fi­nanc­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.